risperidone


( Last Updated : September 27, 2021)
Generic Name:
risperidone
Project Status:
Active
Therapeutic Area:
Schizophrenia, adults
Manufacturer:
HLS Therapeutics Inc.
Brand Name:
Perseris
Project Line:
Reimbursement Review
Project Number:
SR0671-000
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
Treatment of schizophrenia in adults.
Submission Type:
Initial
Fee Schedule:
Schedule C
Indications:
Treatment of schizophrenia in adults.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open24-Dec-20
Call for patient/clinician input closed22-Feb-21
Clarification:

- Patient input submission received from Institute for Advancements in Mental Health

Submission received29-Jan-21
Submission accepted12-Feb-21
Review initiated23-Feb-21
Draft CADTH review report(s) provided to sponsor for comment07-May-21
Deadline for sponsors comments18-May-21
CADTH responses on draft review report(s) provided to sponsor09-Jul-21
Expert committee meeting (initial)21-Jul-21
Draft recommendation issued to sponsor03-Aug-21
Draft recommendation posted for stakeholder feedback12-Aug-21
End of feedback period26-Aug-21
Final recommendation issued to sponsor and drug plans08-Sep-21
Final recommendation posted24-Sep-21
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)22-Sep-21
CADTH review report(s) posted